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Is Human Albumin Solution really the best fluid for advanced cirrhosis patients? 
Dear Sirs, 
We read with interest the revised consensus recommendations for management of acute kidney 
injury (AKI) ) in cirrhosis by the International Club of Ascites.1 We are concerned that plasma volume 
expansion only with albumin is recommended for stage 2 and 3 AKI and do not believe that this 
represents a balanced view of the available evidence. No one doubts that fluid resuscitation is an 
integral part of the management of AKI; however, studies to date have not established class 1 
evidence for an advantage of the use of albumin over other colloids or crystalloids.  
It can be argued that albumin may represent a superior fluid resuscitation agent in cirrhotic patients. 
Certainly a recent meta-analysis has confirmed the superiority of albumin compared with artificial 
plasma expanders for large volume paracentesis.2 Albumin is also recommended for spontaneous 
bacterial peritonitis supported by a meta-analysis of four randomised controlled trials (RCTs) 
including 288 patients that demonstrated that albumin infusion prevented renal impairment and 
reduced mortality.3 However, only 10 patients in the control arm in these trials received any fluid at 
all. Indeed these patients received hydroxyethyl starch, which has been withdrawn from clinical use 
as it can cause renal failure.  
Conversely, the intensive care unit (ICU) literature on fluid resuscitation has shown equivalence of 
albumin versus n/saline in several large-scale appropriately powered clinical RCTs that included 
patients with cirrhosis (although one excluded those with ascites). A subsequent meta-analysis 
supported these outcomes in patients with sepsis.4  
Furthermore, albumin treatment is not without potential harm. In a recent study using albumin, 
Thévenot et al 5 found that pulmonary oedema developed in 8/96 (8.3%) patients in the albumin 
group, two of whom died; although a previous study had shown benefit. No mention is made in 
these AKI guidelines about monitoring treatment response, for example, using haemodynamic 
parameters or blood sampling for lactate or mixed venous oxygen saturation. Theoretically, there is 
also a risk of transmission of prion protein diseases. Furthermore, in the UK the cost of albumin is up 
to five times the cost of crystalloids.  
Finally, widespread uptake of these guidelines, which the authors admit are not based on evidence, 
may actually harm the chance of establishing a better evidence base for albumin with current RCTs 
in progress (eg, ATTIRE and INFECIR2i). Therefore, we believe that the clinical practice guidelines 
should include volume expansion with crystalloid or colloid until there has been conclusive clinical 
trial evidence to provide class I evidence.  
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